TY - JOUR
T1 - Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients
AU - Haut, Paul R.
AU - Cohn, Susan
AU - Morgan, Elaine
AU - Hubbell, Maureen
AU - Danner-Koptik, Karina
AU - Olszewski, Marie
AU - Schaff, Mary
AU - Kletzel, Morris
PY - 1998
Y1 - 1998
N2 - Thirty-five pediatric patients, 1-16 years of age (median 6.3 years), with neoplastic solid tumors (n=32) or acute leukemia (n=3) underwent peripheral blood stem cell (PBSC) harvest and transplantation at Children's Memorial Hospital between September 1992 and April 1997. A median of four phereses were performed on each patient. Blood samples from 34 of the 35 patients were harvested through existing double-lumen central catheters, using either a Fenwal CS-3000 or COBE Spectra pheresis machine. The pheresis procedures were well tolerated overall. A median of 3.7×106/kg CD34+ cells were infused (range, 0.2-15.5×106/kg), and all patients engrafted. The median time to an absolute neutrophil count >500/μL was 13 days (range, 9-44 days) and to a platelet count >20,000/μL was 21 days (range, 9-210 days). Two patients died from transplant-related complications. Patients were discharged from the hospital after a median of 22 days (range, 15-64 days). Twenty of the 35 patients are alive, 17 of whom remain disease-free with a median follow-up of 1144 days. According to this study, PBSCs can be successfully harvested and re-infused for marrow reconstitution after myeloablative therapy in children for a variety of pediatric malignancies with low morbidity and mortality.
AB - Thirty-five pediatric patients, 1-16 years of age (median 6.3 years), with neoplastic solid tumors (n=32) or acute leukemia (n=3) underwent peripheral blood stem cell (PBSC) harvest and transplantation at Children's Memorial Hospital between September 1992 and April 1997. A median of four phereses were performed on each patient. Blood samples from 34 of the 35 patients were harvested through existing double-lumen central catheters, using either a Fenwal CS-3000 or COBE Spectra pheresis machine. The pheresis procedures were well tolerated overall. A median of 3.7×106/kg CD34+ cells were infused (range, 0.2-15.5×106/kg), and all patients engrafted. The median time to an absolute neutrophil count >500/μL was 13 days (range, 9-44 days) and to a platelet count >20,000/μL was 21 days (range, 9-210 days). Two patients died from transplant-related complications. Patients were discharged from the hospital after a median of 22 days (range, 15-64 days). Twenty of the 35 patients are alive, 17 of whom remain disease-free with a median follow-up of 1144 days. According to this study, PBSCs can be successfully harvested and re-infused for marrow reconstitution after myeloablative therapy in children for a variety of pediatric malignancies with low morbidity and mortality.
KW - PBSC
KW - Pediatrics
KW - Transplant
UR - http://www.scopus.com/inward/record.url?scp=0031610287&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031610287&partnerID=8YFLogxK
U2 - 10.1053/bbmt.1998.v4.pm9701390
DO - 10.1053/bbmt.1998.v4.pm9701390
M3 - Article
C2 - 9701390
AN - SCOPUS:0031610287
SN - 1083-8791
VL - 4
SP - 38
EP - 42
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 1
ER -